|
| |
Prolysis
And Essential Science Announce Commercial Collaboration
Oxford, June 7 2004 – Prolysis Ltd, a private company focused on the discovery and development of novel antibiotic therapies, and Essential Science Ltd, the technology exploitation company, today announced the establishment of a collaboration focused on the commercialisation of Prolysis’ novel bacterial cell biology expertise. The agreement will concentrate on the exploitation of Prolysis’ class-leading antibiotic screening assay technology, which the Company plans to make available on a collaborative basis to interested parties.
Essential Science will provide business development support to Prolysis aimed at establishing long-lasting relationships in the areas of library screening, in-licensing of development candidates, out-licensing of Prolysis technologies and development of new applications for Prolysis technology.
Prolysis’ novel bacterial cell biology technology is founded on the pioneering work of Professor Jeff Errington FRS from the Sir William Dunn School of Pathology at the University of Oxford. Based on this work, the Prolysis team has established five proprietary whole cell assays that target critical pathways ensuring that potential therapeutics can enter the bacterial cell. All five assays have been validated with multiple hits and with the advancement of one Prolysis program to lead optimisation stage against a target of significant pharmaceutical interest. Prolysis uses its proprietary high-throughput “dual-reporter” assay system complemented by state-of-the-art fluorescent microscopy for an information-rich understanding of target hits.
Commenting on the collaboration, Steve Ruston CEO of Prolysis said, “We are delighted to be working with Essential Science to realise the full commercial potential of our screening assay technology”
For Essential Science, Neil Murray, CEO, commented, “We are pleased to be working with Prolysis, helping them to exploit the value inherent in their bacterial cell biology technology. The combination of this exciting technology with Essential Science’s innovative business model should allow us to generate significant benefit for
Prolysis.”
-ends-
Prolysis, based in Oxfordshire, UK, is a research and development company focused on the creation of medicines to address the spreading crisis of antibiotic resistance. The Company is exploiting unique insights into bacterial cell biology to create the new broad-spectrum antibiotics that are urgently needed to treat resistant hospital and community-acquired infections. Prolysis has an internal expertise in bacterial cell biology and combines this with structural biology and medicinal chemistry from technology partners to create a multi-project preclinical portfolio. Prolysis will commercialise its new antibiotics by out-licensing after demonstrating proof-of-concept in human Phase IIa studies.
Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.
Further enquiries:
Northbank Communications Ltd
Dr Douglas Pretsell or Sue Charles
Tel: +44 (0)20 7886 8150
d.pretsell@northbankcommunications.com
s.charles@northbankcommunications.com
Prolysis Ltd
Dr Steven Ruston, CEO
Tel: 01865 854 700
steve.ruston@prolysis.com
Essential Science Ltd
Dr Neil Murray, CEO
Tel: 01301 703316
neil@essentialscience.co.uk
| |
|
